

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Pipeline Review, H2 2018

<https://marketpublishers.com/r/CDAD3939154EN.html>

Date: September 2018

Pages: 60

Price: US\$ 3,500.00 (Single User License)

ID: CDAD3939154EN

Abstracts

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Pipeline Review, H2 2018

SUMMARY

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) pipeline Target constitutes close to 18 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes. The latest report CD40 Ligand - Pipeline Review, H2 2, outlays comprehensive information on the CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - CD40 ligand or CD40L is a protein that is primarily expressed on activated T cells and is a member of the TNF superfamily. The CD40-CD40 ligand interaction is crucial to the development of T dependent immune responses. The ligand is expressed on a range of cell types including B cells, granulocytes, macrophages and platelets. T cells expressing CD40L provide signals to B cells that induce proliferation, immunoglobulin class switching,

antibody secretion, and rescue from apoptosis at different times during the life of a B cell and also have a role in the development of germinal centres and the survival of memory B cells. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 1, 3 and 11 respectively.

Similarly, the universities portfolio in Phase II and Preclinical stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Central Nervous System and Infectious Disease which include indications Graft Versus Host Disease (GVHD), Amyotrophic Lateral Sclerosis, Autoimmune Disorders, Breast Cancer, Bladder Cancer, Glioblastoma Multiforme (GBM), Hepatitis B, Hepatocellular Carcinoma, Inflammation, Lung Adenocarcinoma, Melanoma, Metastatic Melanoma, Non-Small Cell Lung Cancer, Pancreatic Cancer, Rheumatoid Arthritis, Sicca Syndrome (Sjogren), Solid Tumor and Systemic Lupus Erythematosus.

Furthermore, this report also reviews key players involved in CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG)

The report reviews CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics and enlists all their major and minor projects

The report assesses CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading

companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Overview

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Companies Involved in Therapeutics Development

DNatrix Inc

eTheRNA Immunotherapies NV

Sanofi

TILT Biotherapeutics Ltd

UCB SA

XL-protein GmbH

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Drug Profiles

AT-1501 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dapirolizumab pegol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Delta-24-RGDOX - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ECI-006 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Proteins for Inflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Target CD40 Ligand for Malignant Melanoma and Bladder Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hepatitis B vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INX-021 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ISF-35 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

letolizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LOAd-700 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NJA-730 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TDI-28 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TILT-234 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target Cancer Testis Antigen, CD80 and CD40L for Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target CD40L and GM-CSF for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VIB-4920 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XL-050 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Dormant Products

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Product Development Milestones

Featured News & Press Releases

May 24, 2018: eTheRNA Enrols First Patient in High Dose Cohort of Phase 1b study of TriMix mRNA-based Cancer Specific Immunotherapy (ECI-006) in Melanoma

Mar 19, 2018: eTheRNA completes enrolment of low dose cohort for Phase 1b study of TriMix mRNA-based cancer specific immunotherapy (ECI-006) in melanoma

Jun 30, 2017: etherna Advances in-vivo MRNA Cancer Immunotherapy Into First

Oncology Clinical Studies

Jun 08, 2016: UCB presents Phase 1 results for dapirolizumab pegol at the Annual European Congress of Rheumatology (EULAR 2016)

Nov 17, 2015: Memgen Announces Preclinical Results for ISF35 in Combination with Checkpoint Inhibitors in a Model of Metastatic Melanoma

Dec 19, 2011: ALS Therapy Development Institute Announces Research Agreement With Biogen Idec And UCB To Investigate Role Of CD40L In ALS

Dec 07, 2011: Memgen Announces Upcoming Presentation For ISF35 In Chronic Lymphocytic Leukemia At 2011 ASH Annual Meeting

Jun 21, 2011: Memgen Presents Clinical Results For ISF35 In Chronic Lymphocytic Leukemia At ASCO 2011

Dec 09, 2010: Memgen Announces Clinical And Preclinical Results For ISF35 In Chronic Lymphocytic Leukemia And Non-Hodgkin's Lymphoma

Dec 08, 2009: Memgen Announces Positive Data Results Of ISF35 For Chronic Lymphocytic Leukemia

Dec 08, 2009: Memgen's ISF35 Sensitizes Cancer Cells To Chemotherapy

Dec 02, 2009: Memgen Selects Clinical Trial Results Of ISF35 For An Oral Presentation At ASH 2009 Annual Meeting

Dec 01, 2009: Memgen's Clinical Trial Results Of ISF35 For Chronic Lymphocytic Leukemia Selected For Presentation At ASH 2009 Annual Meeting

Jun 08, 2009: Memgen Reports Positive Results For ISF35 In High-Risk Chronic Lymphocytic Leukemia

Jun 04, 2009: Memgen Reports Positive Results For ISF35 In High-Risk Chronic Lymphocytic Leukemia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indication, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Number of Products under Investigation by Universities/Institutes, H2 2018

Products under Investigation by Universities/Institutes, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by DNAtrix Inc, H2 2018

Pipeline by eTheRNA Immunotherapies NV, H2 2018

Pipeline by Sanofi, H2 2018

Pipeline by TILT Biotherapeutics Ltd, H2 2018

Pipeline by UCB SA, H2 2018

Pipeline by XL-protein GmbH, H2 2018

Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd.1), H2 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

COMPANIES MENTIONED

DNAtrix Inc

eTheRNA Immunotherapies NV

Sanofi

TILT Biotherapeutics Ltd

UCB SA

XL-protein GmbH

I would like to order

Product name: CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Pipeline Review, H2 2018

Product link: <https://marketpublishers.com/r/CDAD3939154EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CDAD3939154EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

